Mizagliflozin clinical trials
How each study uses mizagliflozin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mizagliflozin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Mizagliflozin
- 2
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
Who runs them
Industry 3 · Other 0
Vogenx, Inc. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test mizagliflozin.
- Oct 2027Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric HypoglycemiaPhase 2 · Vogenx, Inc.
Studies
Open first, then newest update. How each study uses mizagliflozin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric HypoglycemiaRecruitingPhase 2Vogenx, Inc.NCT07760961Written as Mizagliflozin 5 mg
- Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose ExcursionsCompletedPhase 2Vogenx, Inc.NCT05721729Written as Mizagliflozin
- Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia SubjectsCompletedPhase 2Vogenx, Inc.NCT05541939Written as Mizagliflozin
Codes
What other systems call mizagliflozin · ClinicalTrials.gg INT000825
- MeSH (NLM) C000624546mizagliflozinOne source ClinicalTrials.gov
- UNII (FDA) 1X96A704XVMIZAGLIFLOZINConfirmed FDA, Wikidata
- Wikidata Q27253060mizagliflozinConfirmed FDA, Wikidata
- NCI Thesaurus C166520MizagliflozinOne source FDA
- DrugBank DB19036One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624546 | mizagliflozin | One source ClinicalTrials.gov |
| UNII (FDA) | 1X96A704XV | MIZAGLIFLOZIN | Confirmed FDA, Wikidata |
| Wikidata | Q27253060 | mizagliflozin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166520 | Mizagliflozin | One source FDA |
| DrugBank | DB19036 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.